EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications – Regeneron

1. EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications  Regeneron
2. Regeneron Announces FDA Approval of EYLEA HD® for Retinal Vein Occlusion with New Dosing Options  Quiver Quantitative
3. Regeneron announces FDA approval for Eylea HD Injection 8 mg for macular edema  TipRanks
4. Regeneron stock rises as EYLEA HD gets FDA approval for new indication  Investing.com
5. FDA approves EYLEA HD for retinal vein occlusion with extended dosing  Investing.com India

Continue Reading